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ABSTRACT
Background/purpose Early diagnosis of inﬂammatory
rheumatic diseases is important in order to improve
long-term outcome. We studied whether delay in
diagnosis (time between onset of symptoms and
establishment of diagnosis) in patients with rheumatoid
arthritis (RA), psoriatic arthritis (PSA) and ankylosing
spondylitis (AS) changed from year 2000 to 2011.
Methods Month and year of initial symptoms and
diagnosis, gender, hospital, year of birth and date of
ﬁrst data entry were obtained for 13 721 patients with
RA, PSA or AS who had been registered in the DANBIO
registry. Time between symptom onset and diagnosis
was modelled using generalised linear regression to
predict the average duration for each calendar year of
initial symptoms with adjustments for gender, year of
birth and date of DANBIO entry.
Results Patients with valid data (RA: 10 416 (73%); PSA:
1970 (68%); AS: 1335 (65%)) did not differ signiﬁcantly
from the whole DANBIO population, except more missing
data in early years. The regression model showed that the
mean duration from initial symptoms to diagnosis for RA,
PSA and AS declined steadily from 30, 53 and 66 months
(year 2000), respectively, to 3–4 months (year 2011).
Sensitivity analyses including patients who were included
after 2005, patients who had received biological treatment
or had symptom onset less than 2 and 5 years prior to ﬁrst
entry into DANBIO showed similar results.
Conclusion Since the year 2000, a signiﬁcant reduction
in diagnostic delay was observed in this large cohort of
patients with RA, PSA or AS, probably reﬂecting a stronger
awareness of the importance of early diagnosis.
INTRODUCTION
Rheumatoid arthritis (RA), psoriatic arthritis (PSA)
and ankylosing spondylitis (AS) are the most preva-
lent chronic inﬂammatory arthritides, causing severe
pain, joint destructions, loss of function and
comorbidities.1–4 Since the 1990s, scientiﬁc evidence
has shown that the prognosis for patients with RA
improved when they are diagnosed early after
symptom onset.5–8 Early diagnosis and aggressive
treatment with anti-inﬂammatory disease-modifying
drugs such as methotrexate resulted in reduced pro-
gression of joint damage.5–8 The goal of early treat-
ment has so far been difﬁcult to achieve with reports
of lag time between symptom onset and diagnosis of
9–17 months.9 10 A ‘window of opportunity’ for
initiation of treatment of about 3 months after
symptom onset in RA has been identiﬁed as the
optimum time to achieve remission.11 This knowl-
edge is reﬂected in clinical referral and treatment
guidelines across Europe and in the USA, and initia-
tives have been taken to reduce diagnostic delay, for
example, by establishing early arthritis clinics and
referral guidelines.12 The principle of early referral
has spread to other inﬂammatory rheumatic diseases,
for example, PSA and AS.3 13 14 Current recommen-
dations for the management of PSA state that early
treatment should be given priority.3 In AS, the chal-
lenges are even bigger since diagnosing patients has
often been delayed by many years.13 15–17 Thus, con-
siderable and continuous concern has been expressed
by rheumatologists regarding the problem of diagnos-
tic delay in inﬂammatory arthritis.9 12 18–20
Despite this, little is known about whether the
recommendations of early referral have been trans-
formed into more rapid establishment of diagnosis
in routine care. Early referral is difﬁcult to study on
a larger scale because in contrast to the date of
diagnosis, the date of symptom onset is not regis-
tered routinely in patient registration systems.
Based on the nationwide, Danish DANBIO regis-
try, the aim of the present study was to study
whether diagnostic delay deﬁned as the time
between onset of symptoms and the time of diag-
nosis has changed since the year 2000 in patients
with RA, PSA or AS. We hypothesised that a reduc-
tion in diagnostic delay had occurred in this period
for all three diagnoses.
METHODS
Study design
This was an observational study of patients with
RA, PSA or AS who had been registered prospect-
ively in DANBIO between 2000 and 2011. The
main variable of interest was the delay in establish-
ing the diagnosis, that is, the time span between
onset of symptoms and establishment of diagnosis.
We studied changes in delay during the 12-year
period.
Data sources and variables
The DANBIO registry was established in 2000 with
the primary aim to study drug efﬁcacy and
safety.21–25 Rheumatologists from all Danish
departments of rheumatology register adult patients
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(age ≥18 years) with rheumatic disease (ie, RA, AS and PSA)
who start any antirheumatic treatment in routine care. Patients
are followed prospectively with regular registrations of treat-
ment and disease status.23 From 2000 to 2005, the registration
included mainly patients starting treatment with biological
disease-modifying antirheumatic drugs (bDMARDs). Coverage
is >90% for patients who are treated with bDMARDs.23 Since
2005 patients have been registered in DANBIO regardless of
treatment. At the time of inclusion, the treating rheumatologist
enters details of the disease history (including month and year
of symptom onset and of diagnosis), disease activity and anti-
rheumatic treatment. At the time of the ﬁrst registration in
DANBIO, some patients would have recent-onset arthritis and
others established disease.
We obtained information of diagnosis (ICD-10), month/year
of initial symptoms, month/year of diagnosis. gender, birth year,
hospital, geographical region and date of ﬁrst entry into the
DANBIO registry, disease activity at ﬁrst entry (assessed by
patient’s global score on a visual analogue scale ranging from
0 mm (none) to 100 mm (worst possible)), disease severity
(assessed by functional status by the Health Assessment
Questionnaire (HAQ)) and ever/never treatment with
bDMARD.
Study population
The study population included all patients aged ≥18 years at the
time of symptom onset who during the period from January
2000 to December 2011 had been registered in the DANBIO
registry with a diagnosis of RA, PSA or AS and had valid data
on dates of symptom onset and diagnosis.
Potential confounders
As potential confounders were considered demographic vari-
ables (birth year, gender, geographical region) and year of ﬁrst
entry into DANBIO. In patients with available data, analyses
were repeated with addition of the following variables: disease
activity at entry into DANBIO (patient global score), disease
severity (estimated by the HAQ at entry into DANBIO) and pre-
scription of bDMARD (ever/never). Since the results of the two
analyses were similar, we only present the former in the paper.
Permissions and ethics
The DANBIO database has been approved by the Danish Board
of Health and the Danish Data Registry. The registration of data
does not require patient consent. Publication of data does not
require approval by the ethics committee.
Statistical analyses
Valid dates on symptom onset and diagnosis were available for
13 721 of 19 127 patients (72%). We used t test to ascertain asso-
ciation with invalid dates and gender, birth year, symptom onset,
diagnosis, date of data entry and regional health authority. A
total of 120 patients with RA, 58 patients with AS and 126
patients with AS who had delay in diagnosis exceeding
240 months were truncated at 240 months in order to reduce
variance. For the statistical analysis, birth year was categorised
into 10-year age groups (prior to 1929, 1930–1939, …,1980–
1989) and one 5-year group from 1990 to 1995. The years of
ﬁrst symptoms and diagnosis were categorised into 3-year
periods (prior to 2000, 2000–2002, 2003–2005, 2006–2008,
2009–2011). The majority of data on time of ﬁrst symptoms and
ﬁrst diagnosis were entered into DANBIO after 2005. Date of
ﬁrst entry into the DANBIO registry was therefore categorised
into 3-year periods (prior to 2006, 2006–2008, 2009–2011). Up
to 2006 the health service in Denmark was organised in 15 coun-
ties. From 2007 they were amalgamated into ﬁve health regions,
which were used for the present analyses. The study population
was compared with the group of other DANBIO patients who
were excluded from the analysis due to missing data on onset of
symptoms and/or date of diagnosis.
Bivariate analyses were conducted with ordinary least-squares
regressions of the delay as the dependent variable and gender,
year of birth, initial symptoms and calendar year of DANBIO
entry as the explanatory variables. Descriptive analysis of the
average duration of the delay in relation to year of birth and
initial symptoms and year of birth and hospital region was pro-
vided. Kaplan–Meier plots were used to illustrate time from
symptom onset to diagnosis by calendar year of initial
symptoms.
To analyse the association between average delay of diagnosis
and gender, year of birth, year of initial symptoms and year of
entry, three different general linear regression models were esti-
mated: one assuming a Poisson distribution, one negative
binominal regression model (which is less restrictive than the
Poisson model) and ﬁnally a model that assumed a γ distribu-
tion. The model assuming a γ distribution was chosen as the
preferred model because it provided the best ﬁt. This model was
then used to predict the average duration for each year of initial
symptoms with adjustments for gender, year of birth and
DANBIO entry.
Sensitivity analyses were performed including (1) only
patients starting biological treatment, (2) only patients included
in DANBIO after 2005 regardless of treatment, (3) only patients
with recent-onset symptoms deﬁned as maximum 2 years before
ﬁrst registration in DANBIO and (4) only patients with recent
or intermediate duration of symptoms, that is, maximum
5 years before ﬁrst registration.
Statistical analyses were conducted with Stata V.13.0.
Statistical signiﬁcance was assumed for p<0.05.
RESULTS
A total of 10 416 patients with a diagnosis of RA, 1970 patients
with PSA and 1335 with AS were registered in DANBIO before
31 December 2011 and had valid dates of symptom onset and
diagnosis. Thus, 13 721 patients were included in the present
study (table 1). Patients who were included had similar distribu-
tion of gender and age as had those who were not included
(table 1). Signiﬁcantly more patients had missing data in the
early years of DANBIO registration, especially prior to 2005
(ﬁgure 1). When compared with the included patients, the
HAQ score and the patient’s global score on a visual analogue
scale from 0 to 100 mm were higher in the excluded RA and
PSA patients, and the fraction who had ever received biological
treatment was higher in all three groups (table 1).
Characteristics of patients with RA, PSA and AS according to
distribution of gender, birth year, year of ﬁrst symptoms, year of
ﬁrst diagnosis, year of data entry into DANBIO and geograph-
ical region are presented in online supplementary table S1.
During the study period, the average time from initial symp-
toms to diagnosis was 23 months (SD=41) for patients with
RA, 41 (SD=57) for patients with PSA and 88 (SD=79) for
patients with AS. A total of 34% of the RA population, 21% of
the PSA and 9% of the AS patients, respectively, had the diagno-
sis established within 3 months. Figure 2 shows the time from
symptom onset to diagnosis by calendar year of initial symp-
toms. In patients with RA who experienced initial symptoms in
2000–2002, the mean duration until diagnosis was 24 months
(median 12) while for those who experienced initial symptoms
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in 2009–2011 the mean was 6 months (median 4). For patients
with PSA, it was 42 (32) and 7 (5), and for patients with AS 64
(61) and 10 (8), respectively.
Figure 3 illustrates the association between year of symptom
onset (x-axis), year of birth (z-axis) and duration of diagnostic
delay (y-axis) for each disease. Although younger patients had
longer diagnostic delay, the calendar year of symptom onset
contributed more to delay, that is, patients with more recent
symptom onset had shorter diagnostic delay.
For all three diagnoses, the regression model showed that the
calendar year of symptom onset contributed highly signiﬁcantly
and independent of year of birth, year of entry into DANBIO,
gender or geographical region to the duration of the diagnostic
delay. Year of birth also contributed independently, but only in
patients with RA. Gender was only statistically signiﬁcant in
patients with PSA. The year of entry into DANBIO contributed
to a lesser extent. Figure 4 shows the modelled duration of diag-
nostic delay for different years of symptom onset (after adjust-
ment for gender, birth year and year of data entry). The
adjusted duration for individuals who had initial symptoms of
RA in 2000 was more than 29 months, and the adjusted dur-
ation declined each year until the lowest of about 3 months in
2011. For patients with symptoms of PSA and AS, the corre-
sponding delays were 53 and 66 months in 2000 and 3 and
4 months in 2011.
In four sensitivity analyses, calculations were repeated on
subsets of patients, including only patients who had (1) received
biological treatment, (2) been registered in DANBIO after 2005
regardless of treatment and (3) less than 2 years and (4) less
than 5 years of symptom duration before entry into DANBIO,
and the results were similar to those on the whole data set (not
shown).
DISCUSSION
Based on the Danish nationwide DANBIO registry, we studied
changes in diagnostic delay in the new millennium in more than
13 000 patients with inﬂammatory rheumatic diseases. A signiﬁ-
cant and consistent decrease in the time between onset of
Table 1 Clinical characteristics of the study population according to diagnosis and compared with the patients who were not included due to
missing date for symptom onset and/or diagnosis
RA PSA AS
Study
population
Not
included
p
Value
Study
population
Not
included
p
Value
Study
population
Not
included
p
Value
N 10 416 3769 – 1970 920 – 1335 717 –
Women (%) 73.2 72.5 0.41 56.0 56.6 0.75 29.1 27.8 0.51
Age at DANBIO entry (years)
(mean (SD))
58.9 (14.0) 58.8 (14.3) 0.81 48.8 (13.0) 50.3 (12.5) <0.01 40.8 (12.4) 43.2 (12.6) <0.01
Patient global VAS score at entry
(VAS, 0–100 mm)
(mean (SD))
46.4 (28.5)
n=9045
53.7 (27.0)
n=3015
<0.01 51.4 (28.7)
n=1736
57.3 (27.5)
n=811
<0.01 55.8 (26.2)
n=996
57.1 (26.9)
n=598
0.34
DAS28-CRP at entry (mean (SD)) 3.9 (1.5)
n=8180
4.4 (1.6)
n=2795
<0.01 3.7 (1.4)
n=1432
4.1 (1.5)
n=657
<0.01 3.0 (1.1)
n=295
3.5 (1.3)
n=195
<0.01
HAQ at entry (mean (SD)) 0.9 (0.7)
n=9028
1.1 (0.8)
n=2935
<0.01 0.8 (0.6)
n=1619
0.9 (0.7)
n=752
<0.01 0.7 (0.6)
n=173
0.9 (0.9)
n=167
<0.01
Ever biological treatment (% of
patients)
31.1 57.2 <0.01 44.7 53.2 <0.01 69.7 77.8 <0.01
AS, ankylosing spondylitis; DAS28-CRP, disease activity score based on C-reactive protein and four variables; HAQ, Health Assessment Questionnaire; PSA, psoriatic arthritis; RA,
rheumatoid arthritis; VAS: visual analogue scale.
Figure 1 Number of patients with
and without data on years for
symptom onset and diagnosis shown
by year of entry into DANBIO for
patients with rheumatoid arthritis,
psoriatic arthritis and ankylosing
spondylitis.
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symptoms and the time of diagnosis was observed between the
years 2000 and 2011. For RA, the delay was 29 months in the
year 2000, and for PSA and AS it was 53 and 66, respectively.
By 2011, the delay was reduced to 3–4 months for all three
diseases.
The sample size in this study was an important strength, with
data collected prospectively during a 12-years period. Data were
captured as part of a prespeciﬁed DANBIO protocol.23 The ini-
tiative to conduct the investigation came from the Danish
Rheumatism Association, who expressed worry about long diag-
nostic delays in Danish arthritis patients. Data were collected
routinely during patients’ visits at the outpatient clinic, but had
not been inspected for the present purpose, before analyses
began. We consider the internal and external validity and gener-
alisability to be high. However, with an observational design,
potential biases must be considered. In the present study,
patients with very mild and very severe disease would be less
likely to be registered in DANBIO, for example, because specia-
lised treatment was not necessary, or the patient was too ill to
register or even died (channelling bias). DANBIO was estab-
lished in 2000, and patients diagnosed before this time would
experience a waiting period before registration was possible and
would not be registered unless they survived long enough
(immortal time bias or survivor selection bias). Left and right
censorship, channelling (leading to selective reporting) and
immortal time bias may have resulted in relatively more patients
with milder disease being registered during the early years, and
more patients with more severe disease during the later years.
Other reasons for channelling, with the opposite effect on
patient recruitment, may also have been at play: in the early
years of DANBIO, registration was restricted to patients who
were eligible to biological drugs (ie, the most severely ill
patients), whereas after 2005, also patients on non-biological
treatments were included. Various sensitivity analyses supported
the robustness of the results. In a subanalysis including only
patients who had received biological drugs, our key ﬁndings
were conﬁrmed. This is reassuring since coverage of this group
of patients has consistently been >90%, thereby almost elimin-
ating channelling bias.23 Recall bias is another potential source
of error: patients with longer disease duration may have difﬁcul-
ties remembering the correct dates for symptom onset. In two
sensitivity analyses, we only included patients with symptom
onset less than 2 or 5 years prior to ﬁrst entry into DANBIO,
respectively, and found a similar pattern of changes over time in
diagnostic delay, indicating that recall bias was not a major
issue. This is supported by a previous study that concluded that
the majority of patients who were diagnosed with AS remem-
bered the age of ﬁrst symptoms with an accuracy of less than
1 year.26 As expected in this kind of registration, which takes
place in a busy clinical setting, missing data were a weakness
with approximately 28% of the patients in the DANBIO registry
excluded from the study population. Reassuringly, comparison
of the included and excluded patients showed only minor (insig-
niﬁcant) differences in patient characteristics. The number of
patients and the completeness of data improved after 2006,
when DANBIO switched from paper-based to electronic capture
of data. It is likely that the temporal changes observed in this
Danish cohort have also resulted in earlier treatment, which is
important for the long-term outcome of the diseases, but we do
not have data to support this since the date of ﬁrst disease-
modifying treatment is not registered on a routine basis in
DANBIO.
Although RA, PSA and AS are the most prevalent chronic
inﬂammatory joint diseases, little is known about the magnitude
of diagnostic delay in patients followed in routine care and
whether it has changed over the years. Recommendations and
guidelines reﬂect that delay of diagnosis is a major challenge,
which needs to be addressed, and strategies promoting early
referral and reducing delays in the diagnosis and management
of inﬂammatory arthritis have been launched.3 12 27 28 There is
ample evidence in RA that early diagnosis and treatment initi-
ation are associated with improved clinical and radiographic
outcomes including the probability of inducing remission.5 6
Remission is now the treatment goal in RA, leading to better
Figure 2 Time from symptom onset to diagnosis by calendar year of initial symptoms: (A) rheumatoid arthritis, (B) psoriatic arthritis and
(C) ankylosing spondylitis.
Clinical and epidemiological research
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long-term outcomes, and delays in diagnosis beyond a window
of opportunity of 3 months are associated with poorer
outcome.5 19 29 30 Signiﬁcant differences in referral time across
Europe have been reported.20 In one study, the median lag time
between symptom onset and referral was 17 months,10 and in a
cohort of 1674 patients with early RA included between 1993
and 2006, the majority of patients were not seen by a
rheumatologist within the 3 months’ window of opportunity.31
Other smaller studies have reported average lag times between 4
and 40 months.9 32–34 PSA was previously considered a mild
disease, but recent evidence shows that, like RA, PSA causes
joint damage, leading to reduced quality of life, impaired func-
tion and also increased mortality.18 35 The disease develops
more severely in patients who present later than 2 years after
Figure 3 Impact of year of symptom
onset and birth cohort on time from
symptom onset to diagnosis:
(A) rheumatoid arthritis, (B) psoriatic
arthritis and (C) ankylosing spondylitis
Clinical and epidemiological research
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symptom onset compared with those who present earlier, which
suggests that also patients with PSA will beneﬁt from early diag-
nosis and treatment, although a ‘window of opportunity’ has
not been deﬁned.18 36 37 Current recommendations state that
despite relative paucity of randomised controlled trials (RCTs),
early treatment should be given priority.3 Most patients with AS
have onset of symptoms in their mid-20s, which is the most pro-
ductive time of life. In the year 2000, the average diagnostic
delay in ≈3000 patients with AS was almost 10 years.26 In
another study, the average delay was 8 years, but decreasing
from 27 years in 1960 to 2 years in 2000.17 In AS, early treat-
ment has not been demonstrated to inﬂuence radiographic
outcome, but if AS is left undiagnosed, continuous pain, stiff-
ness and fatigue are the consequences alongside a potential pro-
gressive loss of spinal mobility and function.13 Early diagnosis is
important because patients with AS early in the disease course
have at least the same level of disease activity and pain as
patients in the later stages. Early diagnosis facilitates early treat-
ment with non-steroidal anti-inﬂammatory drugs, and if neces-
sary, with tumour necrosis factor blockers, which have the best
treatment response in early AS.14 The present study demon-
strates how observational registries reﬂecting clinical practice
can contribute with new knowledge about disease course in
“real-life” patients because the registries provide data that are
neither collected in RCTs nor in administrative health systems.
Although clinical practice, resources, etc., vary between coun-
tries, it is likely that a reduction in diagnostic delay has been
achieved in other countries. Several factors associated with
patient behaviour and referral systems contribute to delay of
diagnosis. A categorisation of delays has been proposed.38 39
where delays are identiﬁed at several stages: patients may take
time to approach their general practitioner (GP) after they have
experienced a swollen joint (patient delay), GPs may attribute
the swollen joint to other conditions, for example, overuse,
degenerative diseases or gout, causing a further delay (GP
delay), and ﬁnally the waiting time to specialists in rheumatol-
ogy may be long (system delay). Strategies for identiﬁcation and
referral of patients with inﬂammatory arthritis have been
launched, including community case ﬁnding strategies, public
awareness programmes, internet and website information in an
attempt to reduce the patient delay, education programmes,
self-administered questionnaires and referral guidelines to
reduce GP delay, and triage of referrals, rapid access services
and early arthritis clinics to reduce system delay.12 Female
patients of older age have been reported to suffer more diagnos-
tic delay, and other demographic and socioeconomic factors also
have a major impact on patients’ referral to specialist treat-
ment.10 31 34 In the present study, these factors were also of
some signiﬁcance, but compared with the impact of calendar
time, their role was modest. The rheumatologic resources have
been fairly constant during the study period. More magnetic
resonance scanners have become available. This has improved
the access to early diagnosis in patients with axial arthritis and
may have contributed to earlier referral in patients with inﬂam-
matory back pain. Since it takes years to develop the radio-
graphic changes, which are mandatory in AS according to the
modiﬁed New York criteria, not all patients have fulﬁlled those
criteria at the time of diagnosis, but rather have been included
based on a clinical/MRI-based diagnosis.
In conclusion, in a large cohort of patients with inﬂammatory
arthritis, the delay between symptom onset and establishment of
diagnosis decreased signiﬁcantly from the year 2000 to the year
2011, probably reﬂecting a stronger awareness of the import-
ance of early diagnosis.
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Figure 4 Time from symptom onset
to diagnosis from the year 2000 to the
year 2011 in 10 416 patients with
rheumatoid arthritis, psoriatic arthritis
and ankylosing spondylitis adjusted for
gender, birth year and year of entry
into DANBIO.
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